Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemnifosbuvir/Ruzasvir - Atea pharmaceuticals

Next Previous
Drug Profile

Bemnifosbuvir/Ruzasvir - Atea pharmaceuticals

Alternative Names: AT-038; AT-527 - Atea Pharmaceuticals; Ruzasvir/Bemnifosbuvir - ATEA pharmaceuticals

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atea Pharmaceuticals
  • Class Amines; Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Fluorinated hydrocarbons; Imidazoles; Indoles; Phosphorus compounds; Purine nucleotides; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis C
  • Phase I Liver disorders; Renal failure

Most Recent Events

  • 30 Jun 2025 Phase-III clinical trials in Hepatitis C (Treatment-naive) in Moldova (PO) (NCT07037277)
  • 24 Jun 2025 Efficacy data from a phase II trial in Hepatitis C released by Atea Pharmaceuticals
  • 06 Jun 2025 Atea Pharmaceuticals plans a phase I trial in healthy volunteers in USA in June 2025 (PO) (NCT07007806)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top